Literature DB >> 7758234

Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial.

P F Plouin1, J Bertherat, G Chatellier, E Billaud, M Azizi, E Grouzmann, J Epelbaum.   

Abstract

OBJECTIVE: The observation that phaeochromocytoma possess specific somatostatin binding sites led us to test the hypothesis that octreotide may have antisecretory potential in patients with phaeochromocytoma. We therefore compared the effects of octreotide and placebo on blood pressure and plasma catecholamines and neuropeptide Y. PATIENTS: Ten consecutive patients referred to a tertiary care centre for the diagnosis and treatment of a phaeochromocytoma. DESIGN AND MEASUREMENTS: We performed a crossover comparison of either three 100 micrograms subcutaneous injections of octreotide over one day or 3 injections of octreotide vehicle over another. Blood pressure was measured over 24 hours on each test day using an automatic ambulatory recorder. Blood samples were collected before (at 0800 and 0900 h) and after (at 1000, 1100, 1200, 1300 and 1500 h) placebo or octreotide injection. Plasma catecholamines were assayed by high-performance liquid chromatography and neuropeptide Y was determined using a two-site amplified enzyme immunoassay. All patients then underwent surgery and tumoral somatostatin binding site density was determined by quantitative autoradiography.
RESULTS: Compared to placebo, octreotide did not alter mean 24-hour ambulatory blood pressure or plasma neuropeptide Y, or plasma or urinary catecholamine, levels. Although a moderate reduction in plasma noradrenaline was found in the two patients with the highest tumoral somatostatin binding site densities, overall octreotide-induced variations in plasma noradrenaline did not correlate with somatostatin binding site density. Blood glucose increased from 5.4 +/- 0.3 on placebo to 7.8 +/- 0.5 mmol/l on octreotide (P < 0.01).
CONCLUSION: In the present controlled conditions, short-term administration of octreotide had no antisecretory effect in patients with phaeochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758234     DOI: 10.1111/j.1365-2265.1995.tb01877.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Vasoactive intestinal peptide secreting tumour: An overview.

Authors:  Esther Una Cidon
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

Review 2.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

3.  Catecholamine-secreting carotid body paraganglioma: successful preoperative control of hypertension and clinical symptoms using high-dose long-acting octreotide.

Authors:  Omayma Elshafie; Yahya Al Badaai; Khalifa Alwahaibi; Asim Qureshi; Samir Hussein; Faisal Al Azzri; Ali Almamari; Ncholas Woodhouse
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-07-01

4.  Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature.

Authors:  Xiao Hu; Wei Cao; Min Zhao
Journal:  World J Clin Cases       Date:  2018-11-26       Impact factor: 1.337

5.  Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma.

Authors:  Alessandro Rossini; Francesca Perticone; Laura Frosio; Marco Schiavo Lena; Roberto Lanzi
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-11-25

6.  Case Report: Irreversible Watery Diarrhea, Severe Metabolic Acidosis, Hypokalemia and Achloridria Syndrome Related to Vasoactive Intestinal Peptide Secreting Malignant Pheochromocytoma.

Authors:  Aurelio Negro; Ignazio Verzicco; Stefano Tedeschi; Nicoletta Campanini; Magda Zanelli; Emanuele Negri; Enrico Farnetti; Davide Nicoli; Barbara Palladini; Rosaria Santi; Davide Cunzi; Anna Calvi; Pietro Coghi; Luigi Gerra; Riccardo Volpi; Gallia Graiani; Aderville Cabassi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-17       Impact factor: 5.555

Review 7.  Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.

Authors:  Paweł Komarnicki; Jan Musiałkiewicz; Alicja Stańska; Adam Maciejewski; Paweł Gut; George Mastorakos; Marek Ruchała
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964

Review 8.  Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case.

Authors:  R M Ruggeri; F Ferraù; A Campennì; A Simone; V Barresi; G Giuffrè; G Tuccari; S Baldari; F Trimarchi
Journal:  Eur J Histochem       Date:  2009-03-31       Impact factor: 3.188

Review 9.  The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor management.

Authors:  J W Kennedy; R G Dluhy
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.